Table 1.
Baseline clinical characteristics of the study population
| NPH + placebo | NPH + metformin | NPH + rosiglitazone | NPH + both | NPH total | ASP + placebo | ASP + metformin | ASP + rosiglitazone | ASP + both | ASP total | |
|---|---|---|---|---|---|---|---|---|---|---|
| n | 46 | 45 | 46 | 46 | 183 | 48 | 45 | 47 | 48 | 188 |
| Sex (F/M) | 13/33 | 19/26 | 18/28 | 16/30 | 66/117 | 25/23 | 17/28 | 20/27 | 13/34 | 76/112 |
| Age (years) | 55.8 ± 7.7 | 55.4 ± 8.5 | 57.3 ± 8.9 | 57.3 ± 8.2 | 56.5 ± 8.3 | 57.1 ± 8.5 | 56.1 ± 8.2 | 56.1 ± 8.3 | 55.3 ± 9.1 | 56.2 ± 8.5 |
| Diabetes duration (years) | 7.3 ± 4.3 | 8.2 ± 4.0 | 9.2 ± 6.9 | 8.1 ± 5.3 | 8.2 ± 5.2 | 9.1 ± 5.5 | 8.7 ± 4.5 | 9.4 ± 6.3 | 9.0 ± 5.8 | 9.1 ± 5.5 |
| Body weight (kg) | 100.2 ± 19.8 | 105.1 ± 17.7 | 100.9 ± 16.5 | 101.1 ± 19.3 | 102.1 ± 18.3 | 98.3 ± 16.6 | 100.5 ± 17.9 | 95.6 ± 14.6 | 99.1 ± 16.6 | 98.3 ± 16.4 |
| BMI (kg/m2) | 34.0 ± 6.0 | 35.7 ± 6.4 | 34.0 ± 5.7 | 34.4 ± 7.0 | 34.5 ± 6.3 | 33.7 ± 5.0 | 33.7 ± 6.1 | 32.7 ± 4.7 | 32.9 ± 4.4 | 33.2 ± 5.0 |
| A1C (%) | 8.7 ± 1.3 | 8.9 ± 1.2 | 8.7 ± 1.2 | 8.5 ± 1.1 | 8.7 ± 1.3 | 8.5 ± 1.2 | 8.5 ± 1.2 | 8.3 ± 1.0 | 8.5 ± 1.2 | 8.5 ± 1.1 |
| FPG (mmol/l) | 11.2 ± 2.6 | 11.3 ± 2.8 | 10.5 ± 2.4 | 10.2 ± 2.6 | 10.8 ± 2.6 | 10.7 ± 2.5 | 10.0 ± 2.3 | 9.9 ± 2.1 | 10.3 ± 2.6 | 10.2 ± 2.4 |
| Fasting C-peptide concentration (pmol/l) | 1,063 ± 495 | 1,115 ± 505 | 1,026 ± 554 | 1,099 ± 548 | 1,076 ± 523 | 1,070 ± 528 | 967 ± 460 | 975 ± 440 | 1,000 ± 467 | 1,003 ± 474 |
| Treatment at inclusion* | ||||||||||
| Metformin (%) | 78 | 84 | 70 | 67 | 75 | 71 | 69 | 70 | 63 | 68 |
| Sulfonylurea (%) | 65 | 58 | 46 | 56 | 56 | 48 | 29 | 51 | 52 | 45 |
| Insulin (%) | 29 | 31 | 46 | 30 | 34 | 48 | 53 | 51 | 42 | 48 |
Data are means ± SD unless otherwise stated.
*No patients received glitazone or DDP-4 inhibitor treatment before the study. ASP, insulin aspart; both, metformin + rosiglitazone.